Literature DB >> 33426780

Validation of a Bioassay for Predicting Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis.

Ching-Huang Ho1, Andrea A Silva1, Jon T Giles2, Joan M Bathon2, Daniel H Solomon1, Katherine P Liao1, I-Cheng Ho1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33426780      PMCID： PMC8169520          DOI： 10.1002/art.41645

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN： 2326-5191            Impact factor:   15.483


× No keyword cloud information.
  7 in total

1.  Utilizing a PTPN22 gene signature to predict response to targeted therapies in rheumatoid arthritis.

Authors:  Hui-Hsin Chang; Ching-Huang Ho; Beverly Tomita; Andrea A Silva; Jeffrey A Sparks; Elizabeth W Karlson; Deepak A Rao; Yvonne C Lee; I-Cheng Ho
Journal:  J Autoimmun       Date:  2019-04-26       Impact factor: 7.094

2.  Serum interleukin-6 and survivin levels predict clinical response to etanercept treatment in patients with established rheumatoid arthritis.

Authors:  Rui Shi; Muzhi Chen; Bahaerguli Litifu
Journal:  Mod Rheumatol       Date:  2017-06-28       Impact factor: 3.023

Review 3.  Prediction of Response to Targeted Treatment in Rheumatoid Arthritis.

Authors:  C A Wijbrandts; P P Tak
Journal:  Mayo Clin Proc       Date:  2017-07       Impact factor: 7.616

4.  Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis Patients.

Authors:  J R Curtis; S Yang; L Chen; J E Pope; E C Keystone; B Haraoui; G Boire; J C Thorne; D Tin; C A Hitchon; C O Bingham; V P Bykerk
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-10       Impact factor: 4.794

5.  CD8+ T Cells Specific to Apoptosis-Associated Antigens Predict the Response to Tumor Necrosis Factor Inhibitor Therapy in Rheumatoid Arthritis.

Authors:  Alessandra Citro; Rossana Scrivo; Helene Martini; Carmela Martire; Paolo De Marzio; Anna Rita Vestri; John Sidney; Alessandro Sette; Vincenzo Barnaba; Guido Valesini
Journal:  PLoS One       Date:  2015-06-10       Impact factor: 3.240

6.  Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study.

Authors:  Bobby Kwanghoon Han; Igor Kuzin; John P Gaughan; Nancy J Olsen; Andrea Bottaro
Journal:  Arthritis Res Ther       Date:  2016-04-22       Impact factor: 5.156

Review 7.  Using the Immunophenotype to Predict Response to Biologic Drugs in Rheumatoid Arthritis.

Authors:  Ben Mulhearn; Anne Barton; Sebastien Viatte
Journal:  J Pers Med       Date:  2019-10-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.